These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. Meltzer HY; Busch D Psychiatry Res; 1983 Aug; 9(4):285-99. PubMed ID: 6580661 [TBL] [Abstract][Full Text] [Related]
43. On the role of dopamine receptors in the central regulation of human TSH. Delitala G; Devilla L; Canessa A; D'Asta F Acta Endocrinol (Copenh); 1981 Dec; 98(4):521-7. PubMed ID: 7304078 [TBL] [Abstract][Full Text] [Related]
45. Dopamine uptake by platelets from subjects with schizophrenia: a correlation with the delusional state of the patient. Dean B; Kulkarni J; Copolov DL; Shrikanthan P; Malone V; Hill C Psychiatry Res; 1992 Jan; 41(1):17-24. PubMed ID: 1561286 [TBL] [Abstract][Full Text] [Related]
46. Effect of ergovaline, loline, and dopamine antagonists on rat pituitary cell prolactin release in vitro. Strickland JR; Cross DL; Birrenkott GP; Grimes LW Am J Vet Res; 1994 May; 55(5):716-21. PubMed ID: 8067623 [TBL] [Abstract][Full Text] [Related]
47. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine. Whalley LJ; Christie JE; Brown S; Arbuthnott GW Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565 [TBL] [Abstract][Full Text] [Related]
48. Prolactin responses to haloperidol in drug-free and treated schizophrenic patients. Markianos M; Sakellariou G; Bistolaki E J Neural Transm Gen Sect; 1991; 83(1-2):37-42. PubMed ID: 2018629 [TBL] [Abstract][Full Text] [Related]
49. Relation of plasma prolactin to clinical response in schizophrenic patients. Gruen PG; Sachar EJ; Altman N; Langer G; Tabrizi MA; Halpern FS Arch Gen Psychiatry; 1978 Oct; 35(10):1222-7. PubMed ID: 29592 [TBL] [Abstract][Full Text] [Related]
50. Suppression of prolactin by dopamine agonists in schizophrenics and controls. Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840 [TBL] [Abstract][Full Text] [Related]
51. [Kinetics of prolactinemia after withdrawal of dopamine perfusion and during the administration of domperidone. Normal and hyperprolactinemic subjects (prolactinomas and suprahypophyseal lesions)]. Bercovici JP; Khoury S; Tater D; Besson G; Caroff J Biomed Pharmacother; 1983; 37(5):222-7. PubMed ID: 6661508 [TBL] [Abstract][Full Text] [Related]
52. Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinaemic women after dopamine synthesis blockade. Ghigo E; Goffi S; Molinatti GM; Camanni F; Massara F Clin Endocrinol (Oxf); 1985 Aug; 23(2):155-60. PubMed ID: 3931942 [TBL] [Abstract][Full Text] [Related]
53. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients. Faraone SV; Brown WA; Laughren TP J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923 [TBL] [Abstract][Full Text] [Related]
54. Effects of pimozide and domperidone administration on prolactin levels in neonatally estrogenized female rats. Aguilar E; López F; Pinilla L; Bellido C; Vaticón MD Rev Esp Fisiol; 1985 Jun; 41(2):183-6. PubMed ID: 4041067 [TBL] [Abstract][Full Text] [Related]
55. Associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated schizophrenics: relevance to supersensitivity psychosis. Csernansky JG; Vinogradov S; Prosser E; Kaplan J; Berger PA; Hollister LE Psychopharmacol Bull; 1986; 22(3):897-9. PubMed ID: 2879311 [No Abstract] [Full Text] [Related]
56. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737 [TBL] [Abstract][Full Text] [Related]
57. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia. Sawers HA; Robb OJ; Walmsley D; Strachan FM; Shaw J; Bevan JS Clin Endocrinol (Oxf); 1997 Mar; 46(3):321-6. PubMed ID: 9156042 [TBL] [Abstract][Full Text] [Related]
58. Does endogenous dopamine modulate human sympathetic activity through DA2 receptors? Mannelli M; De Feo ML; Maggi M; Salvetti A; Giusti G; Serio M Eur J Clin Pharmacol; 1985; 29(2):159-64. PubMed ID: 2934264 [TBL] [Abstract][Full Text] [Related]
59. Dysfunction of dopaminergic regulation of prolactin in patients with functioning and nonfunctioning pituitary adenomas and craniopharyngiomas. Martinez-Campos A; Cornejo J; Garza-Flores J; Velasco F Fertil Steril; 1985 Oct; 44(4):471-7. PubMed ID: 4054318 [TBL] [Abstract][Full Text] [Related]
60. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia. Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]